AGFS yields 66.67% · JNJ yields 2.13%● Live data
📍 AGFS pulled ahead of the other in Year 1
Combined, AGFS + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of AGFS + JNJ for your $10,000?
AgroFresh Solutions, Inc. provides science-based solutions, data-driven technologies, and high-touch customer services. The company's flagship product is the SmartFresh system that regulates the post-harvest ripening effects of ethylene to preserve the texture, firmness, taste, and appearance of produce during storage, transportation, and retail display. It also provides Harvista technology for use in near-harvest management of apples, pears, cherries, and blueberries; FreshCloud, a digital technology service platform of produce monitoring and screening solutions; and LandSpring, a 1- methlycycloproprene technology targeted to transplanted vegetable seedlings. In addition, the company offers fungicides, disinfectants, coatings, and packinghouse equipment for the citrus market under the Actiseal, FreshStart, VitaFresh Botanicals, Teycer Originals, and Control-Tec brands. It supports growers, packers, and retailers with solutions across the food supply chain to enhance the shelf life of fresh produce. The company primarily operates in the United States, Canada, Argentina, Brazil, Chile, Columbia, Costa Rica, the Dominican Republic, Ecuador, Guatemala, Mexico, Peru, Uruguay, Europe, the Middle East, Africa, Australia, China, India, Japan, New Zealand, South Korea, and the Philippines. AgroFresh Solutions, Inc. was founded in 1994 and is headquartered in Philadelphia, Pennsylvania.
Full AGFS Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.